Post Title
LOREM IPSUM DOLOR SIT AMET

28 Jun: APRIL trial update: completed enrollment and dosing for Phase 1b

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

01 May: CDTI-PID program

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

01 Apr: APRIL trial (Acute Ischemic Stroke) gets authorization by the ANSM (France) and the BfArM (Germany)

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

29 Oct: aptaTargets starts Phase 1b/2a clinical trial with ApTOLL in stroke patients

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

13 Oct: aptaTargets closes a second round of €5 million

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

28 Jul: RETOS funding for the ApTOLL stroke program

aTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.